TY  - JOUR
AU  - Kalinsky, Kevin
AU  - Barlow, William E
AU  - Gralow, Julie R
AU  - Meric-Bernstam, Funda
AU  - Albain, Kathy S
AU  - Hayes, Daniel F
AU  - Lin, Nancy U
AU  - Perez, Edith A
AU  - Goldstein, Lori J
AU  - Chia, Stephen K L
AU  - Dhesy-Thind, Sukhbinder
AU  - Rastogi, Priya
AU  - Alba, Emilio
AU  - Delaloge, Suzette
AU  - Martin, Miguel
AU  - Kelly, Catherine M
AU  - Ruiz-Borrego, Manuel
AU  - Gil-Gil, Miguel
AU  - Arce-Salinas, Claudia H
AU  - Brain, Etienne G C
AU  - Lee, Eun-Sook
AU  - Pierga, Jean-Yves
AU  - Bermejo, Begoña
AU  - Ramos-Vazquez, Manuel
AU  - Jung, Kyung-Hae
AU  - Ferrero, Jean-Marc
AU  - Schott, Anne F
AU  - Shak, Steven
AU  - Sharma, Priyanka
AU  - Lew, Danika L
AU  - Miao, Jieling
AU  - Tripathy, Debasish
AU  - Pusztai, Lajos
AU  - Hortobagyi, Gabriel N
PY  - 2021
DO  - 10.1056/NEJMoa2108873
UR  - https://hdl.handle.net/10668/27721
T2  - The New England journal of medicine
AB  - The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary lymph-node-negative breast...
LA  - en
PB  - Massachusetts Medical Society
KW  - Antineoplastic Agents, Hormonal
KW  - Disease-Free Survival
KW  - Lymphatic Metastasis
KW  - Premenopause
KW  - Receptor, ErbB-2
KW  - Reverse Transcriptase Polymerase Chain Reaction
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Chemotherapy, Adjuvant
KW  - Female
KW  - Gene Expression Profiling
KW  - Humans
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Premenopause
KW  - Prospective Studies
KW  - Receptors, Steroid
TI  - 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
TY  - research article
VL  - 385
ER  -